Abstract 348P
Background
Effective interventions to improve prognosis in non-small-cell lung cancer (NSCLC) are urgently needed. We assessed the effect of the early integration of interdisciplinary palliative care for patients with NSCLC on the nutritional status, quality of life (QoL), psychological state and cancer pain.
Methods
In this randomised controlled trial, 120 newly diagnosed NSCLC patients were enrolled and randomly assigned (1:1) to the combined early palliative care (CEPC) group integrated with standard oncologic care or standard oncological care (SC) group. QoL and psychological state were assessed at baseline and at 24 weeks by Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9), respectively. Cancer nutritional and pain status were assessed with the use of the Patient-Generated Subjective Global Assessment (PG-SGA) and Numerical Rating Scale (NRS), respectively. The primary outcome was the change in the quality of life, psychological state and nutritional status at 24 weeks. Analysis was by intention to treat.
Results
120 patients were enrolled: 60 in CEPC group (38 completed) and 60 in the SC group(32 completed). Patients in CEPC group had a better nutritional status [severe malnutrition: 11.67% (7/60); mild or moderate malnutrition: 61.67% (37/60); no malnutrition: 26.67% (16/60)] than SC group[severe malnutrition: 36.67% (22/60); mild or moderate malnutrition: 55.0% (33/60); no malnutrition: 8.3% (5/60)] (P=0.001). Furthermore, CEPC group had a better QoL than SC group (P<0.05). In addition, fewer patients in the CEPC group than in the SC group had depressive (P=0.005) symptoms. There was no significant difference in NRS score between CEPC group and SC group.
Conclusions
Among patients with non-small-cell lung cancer, early palliative care led to significant improvements in nutritional status, quality of life and psychological state.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
318P - EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
Presenter: Miranda Gogishvili
Session: Poster viewing 05.
323P - Development of a model to predict PD-L1 expression in pulmonary squamous cell carcinoma based on CT imaging features
Presenter: Yun Kyoung Shin
Session: Poster viewing 05.
324P - Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
Presenter: Qin Shi
Session: Poster viewing 05.
326P - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
Presenter: Byoung Chul Cho
Session: Poster viewing 05.
328P - Long-term follow-up of pembrolizumab plus chemotherapy in Chinese patients with metastatic squamous non-small cell lung cancer (NSCLC) from KEYNOTE-407
Presenter: Ying Cheng
Session: Poster viewing 05.
329P - ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
Presenter: Jonathan Riess
Session: Poster viewing 05.
332P - A phase II, open-label, single-center study of QL1706 plus platinum doublet chemotherapy with bevacizumab as first-line treatment in patients with advanced NSCLC: Data from EGFR mutant cohort
Presenter: Wen Feng Fang
Session: Poster viewing 05.